Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer
Background The prognosis of patients with non-small cell lung cancer (NSCLC) is important, as patients with resectable disease and poor prognostic variables might benefit from neoadjuvant therapy. The goal of this study is to evaluate SUVmax, SUVmax ratio, CT volume (CTvol), metabolic tumour volume...
Gespeichert in:
| Veröffentlicht in: | European radiology 2015-11, Vol.25 (11), p.3361-3367 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3367 |
|---|---|
| container_issue | 11 |
| container_start_page | 3361 |
| container_title | European radiology |
| container_volume | 25 |
| creator | Domachevsky, L. Groshar, D. Galili, R. Saute, M. Bernstine, H. |
| description | Background
The prognosis of patients with non-small cell lung cancer (NSCLC) is important, as patients with resectable disease and poor prognostic variables might benefit from neoadjuvant therapy. The goal of this study is to evaluate SUVmax, SUVmax ratio, CT volume (CTvol), metabolic tumour volume (MTV) and total lesion glycolisis (TLG) as survival prognostic markers. In addition, we defined two variables; MTV x SUVmax (MTVmax) and CTvol x SUVmax (CTvolmax) and assessed whether they can be used as prognostic markers.
Methods
Patients with stage I-II NSCLC who underwent 18 F FDG PET/CT and surgery were evaluated. Cox proportional-hazard model was used to determine the association between variables and survival. Similar analysis was performed in cases with no lymph node (LN) involvement.
Results
One hundred and eighty-one patients were included (at the end of the study, 140 patients were alive). SUVmax with a cut-off value of 8.2 was significant survival prognostic factor regardless of LN involvement (P = 0.012). In cases with no LN involvement, SUVmax and CTvol (≥7.1 ml) were significant survival prognostic factors with P = 0.004 and 0.03, respectively.
Conclusions
SUVmax may be a useful prognostic variable in stage I-II NSCLC while morphologic tumour volume might be useful in cases with no lymph node involvement.
Key Points
•
Identifying variables that predict the prognosis of patients with NSCLC is important.
•
SUVmax in primary lung tumour is a useful independent prognostic variable
.
•
(CTvol) is an independent prognostic variable if no lymph nodes are involved
. |
| doi_str_mv | 10.1007/s00330-015-3754-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1720447464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1720447464</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-3dd99fefffd06270c781550748d964e74636caa92e18b5bffaafe2841d1bc7c3</originalsourceid><addsrcrecordid>eNp1kUFrHCEYhiW0NNu0PyCXIPTSi-mn44zjsSxturBpAxt6FcfRiWFWtzqzJYf895hsWkKhFwV93tcPH4ROKZxTAPEpA1QVEKA1qUTNSXuEFpRXjFBo-Su0AFm1REjJj9HbnG8BQFIu3qBjVktWjmGB7jdz2vu9HvFVikOIefIG_9TjbHF0-DKm3U0c4-BNIXTo8aWddBfHAu118robbcY-4Cs9eRumjH_76QZvJj1YvHoKrFb4ewxks9XjiJe2LOs5DHipg7HpHXrt9Jjt--f9BF1__XK9_EbWPy5Wy89rYjhnE6n6XkpnnXM9NEyAES2taxC87WXDreBN1RitJbO07erOOa2dZS2nPe2MMNUJ-nio3aX4a7Z5UlufTZlFBxvnrKhgwHmp4QX98A96G-cUynCFopI35RObQtEDZVLMOVmndslvdbpTFNSjGnVQo4oa9ahGtSVz9tw8d1vb_038cVEAdgByuQqDTS-e_m_rA_hmmSM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1719460006</pqid></control><display><type>article</type><title>Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Domachevsky, L. ; Groshar, D. ; Galili, R. ; Saute, M. ; Bernstine, H.</creator><creatorcontrib>Domachevsky, L. ; Groshar, D. ; Galili, R. ; Saute, M. ; Bernstine, H.</creatorcontrib><description>Background
The prognosis of patients with non-small cell lung cancer (NSCLC) is important, as patients with resectable disease and poor prognostic variables might benefit from neoadjuvant therapy. The goal of this study is to evaluate SUVmax, SUVmax ratio, CT volume (CTvol), metabolic tumour volume (MTV) and total lesion glycolisis (TLG) as survival prognostic markers. In addition, we defined two variables; MTV x SUVmax (MTVmax) and CTvol x SUVmax (CTvolmax) and assessed whether they can be used as prognostic markers.
Methods
Patients with stage I-II NSCLC who underwent 18 F FDG PET/CT and surgery were evaluated. Cox proportional-hazard model was used to determine the association between variables and survival. Similar analysis was performed in cases with no lymph node (LN) involvement.
Results
One hundred and eighty-one patients were included (at the end of the study, 140 patients were alive). SUVmax with a cut-off value of 8.2 was significant survival prognostic factor regardless of LN involvement (P = 0.012). In cases with no LN involvement, SUVmax and CTvol (≥7.1 ml) were significant survival prognostic factors with P = 0.004 and 0.03, respectively.
Conclusions
SUVmax may be a useful prognostic variable in stage I-II NSCLC while morphologic tumour volume might be useful in cases with no lymph node involvement.
Key Points
•
Identifying variables that predict the prognosis of patients with NSCLC is important.
•
SUVmax in primary lung tumour is a useful independent prognostic variable
.
•
(CTvol) is an independent prognostic variable if no lymph nodes are involved
.</description><identifier>ISSN: 0938-7994</identifier><identifier>EISSN: 1432-1084</identifier><identifier>DOI: 10.1007/s00330-015-3754-8</identifier><identifier>PMID: 25929940</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Carcinoma, Non-Small-Cell Lung - diagnostic imaging ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Chest ; Cone-Beam Computed Tomography ; Diagnostic Radiology ; Female ; Fluorodeoxyglucose F18 ; Humans ; Imaging ; Internal Medicine ; Interventional Radiology ; Lung cancer ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lymphatic Metastasis - pathology ; Male ; Medicine ; Medicine & Public Health ; Multimodal Imaging ; Neoadjuvant Therapy ; Neoplasm Staging ; Neuroradiology ; Positron-Emission Tomography ; Prognosis ; Proportional Hazards Models ; Radiology ; Radiopharmaceuticals ; Retrospective Studies ; Tomography, X-Ray Computed ; Tumor Burden ; Ultrasound</subject><ispartof>European radiology, 2015-11, Vol.25 (11), p.3361-3367</ispartof><rights>European Society of Radiology 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-3dd99fefffd06270c781550748d964e74636caa92e18b5bffaafe2841d1bc7c3</citedby><cites>FETCH-LOGICAL-c442t-3dd99fefffd06270c781550748d964e74636caa92e18b5bffaafe2841d1bc7c3</cites><orcidid>0000-0001-8038-8161</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00330-015-3754-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00330-015-3754-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25929940$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Domachevsky, L.</creatorcontrib><creatorcontrib>Groshar, D.</creatorcontrib><creatorcontrib>Galili, R.</creatorcontrib><creatorcontrib>Saute, M.</creatorcontrib><creatorcontrib>Bernstine, H.</creatorcontrib><title>Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer</title><title>European radiology</title><addtitle>Eur Radiol</addtitle><addtitle>Eur Radiol</addtitle><description>Background
The prognosis of patients with non-small cell lung cancer (NSCLC) is important, as patients with resectable disease and poor prognostic variables might benefit from neoadjuvant therapy. The goal of this study is to evaluate SUVmax, SUVmax ratio, CT volume (CTvol), metabolic tumour volume (MTV) and total lesion glycolisis (TLG) as survival prognostic markers. In addition, we defined two variables; MTV x SUVmax (MTVmax) and CTvol x SUVmax (CTvolmax) and assessed whether they can be used as prognostic markers.
Methods
Patients with stage I-II NSCLC who underwent 18 F FDG PET/CT and surgery were evaluated. Cox proportional-hazard model was used to determine the association between variables and survival. Similar analysis was performed in cases with no lymph node (LN) involvement.
Results
One hundred and eighty-one patients were included (at the end of the study, 140 patients were alive). SUVmax with a cut-off value of 8.2 was significant survival prognostic factor regardless of LN involvement (P = 0.012). In cases with no LN involvement, SUVmax and CTvol (≥7.1 ml) were significant survival prognostic factors with P = 0.004 and 0.03, respectively.
Conclusions
SUVmax may be a useful prognostic variable in stage I-II NSCLC while morphologic tumour volume might be useful in cases with no lymph node involvement.
Key Points
•
Identifying variables that predict the prognosis of patients with NSCLC is important.
•
SUVmax in primary lung tumour is a useful independent prognostic variable
.
•
(CTvol) is an independent prognostic variable if no lymph nodes are involved
.</description><subject>Aged</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Chest</subject><subject>Cone-Beam Computed Tomography</subject><subject>Diagnostic Radiology</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Imaging</subject><subject>Internal Medicine</subject><subject>Interventional Radiology</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lymphatic Metastasis - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multimodal Imaging</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Staging</subject><subject>Neuroradiology</subject><subject>Positron-Emission Tomography</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Radiology</subject><subject>Radiopharmaceuticals</subject><subject>Retrospective Studies</subject><subject>Tomography, X-Ray Computed</subject><subject>Tumor Burden</subject><subject>Ultrasound</subject><issn>0938-7994</issn><issn>1432-1084</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUFrHCEYhiW0NNu0PyCXIPTSi-mn44zjsSxturBpAxt6FcfRiWFWtzqzJYf895hsWkKhFwV93tcPH4ROKZxTAPEpA1QVEKA1qUTNSXuEFpRXjFBo-Su0AFm1REjJj9HbnG8BQFIu3qBjVktWjmGB7jdz2vu9HvFVikOIefIG_9TjbHF0-DKm3U0c4-BNIXTo8aWddBfHAu118robbcY-4Cs9eRumjH_76QZvJj1YvHoKrFb4ewxks9XjiJe2LOs5DHipg7HpHXrt9Jjt--f9BF1__XK9_EbWPy5Wy89rYjhnE6n6XkpnnXM9NEyAES2taxC87WXDreBN1RitJbO07erOOa2dZS2nPe2MMNUJ-nio3aX4a7Z5UlufTZlFBxvnrKhgwHmp4QX98A96G-cUynCFopI35RObQtEDZVLMOVmndslvdbpTFNSjGnVQo4oa9ahGtSVz9tw8d1vb_038cVEAdgByuQqDTS-e_m_rA_hmmSM</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Domachevsky, L.</creator><creator>Groshar, D.</creator><creator>Galili, R.</creator><creator>Saute, M.</creator><creator>Bernstine, H.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8038-8161</orcidid></search><sort><creationdate>20151101</creationdate><title>Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer</title><author>Domachevsky, L. ; Groshar, D. ; Galili, R. ; Saute, M. ; Bernstine, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-3dd99fefffd06270c781550748d964e74636caa92e18b5bffaafe2841d1bc7c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Chest</topic><topic>Cone-Beam Computed Tomography</topic><topic>Diagnostic Radiology</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Imaging</topic><topic>Internal Medicine</topic><topic>Interventional Radiology</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lymphatic Metastasis - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multimodal Imaging</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Staging</topic><topic>Neuroradiology</topic><topic>Positron-Emission Tomography</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Radiology</topic><topic>Radiopharmaceuticals</topic><topic>Retrospective Studies</topic><topic>Tomography, X-Ray Computed</topic><topic>Tumor Burden</topic><topic>Ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Domachevsky, L.</creatorcontrib><creatorcontrib>Groshar, D.</creatorcontrib><creatorcontrib>Galili, R.</creatorcontrib><creatorcontrib>Saute, M.</creatorcontrib><creatorcontrib>Bernstine, H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Domachevsky, L.</au><au>Groshar, D.</au><au>Galili, R.</au><au>Saute, M.</au><au>Bernstine, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer</atitle><jtitle>European radiology</jtitle><stitle>Eur Radiol</stitle><addtitle>Eur Radiol</addtitle><date>2015-11-01</date><risdate>2015</risdate><volume>25</volume><issue>11</issue><spage>3361</spage><epage>3367</epage><pages>3361-3367</pages><issn>0938-7994</issn><eissn>1432-1084</eissn><abstract>Background
The prognosis of patients with non-small cell lung cancer (NSCLC) is important, as patients with resectable disease and poor prognostic variables might benefit from neoadjuvant therapy. The goal of this study is to evaluate SUVmax, SUVmax ratio, CT volume (CTvol), metabolic tumour volume (MTV) and total lesion glycolisis (TLG) as survival prognostic markers. In addition, we defined two variables; MTV x SUVmax (MTVmax) and CTvol x SUVmax (CTvolmax) and assessed whether they can be used as prognostic markers.
Methods
Patients with stage I-II NSCLC who underwent 18 F FDG PET/CT and surgery were evaluated. Cox proportional-hazard model was used to determine the association between variables and survival. Similar analysis was performed in cases with no lymph node (LN) involvement.
Results
One hundred and eighty-one patients were included (at the end of the study, 140 patients were alive). SUVmax with a cut-off value of 8.2 was significant survival prognostic factor regardless of LN involvement (P = 0.012). In cases with no LN involvement, SUVmax and CTvol (≥7.1 ml) were significant survival prognostic factors with P = 0.004 and 0.03, respectively.
Conclusions
SUVmax may be a useful prognostic variable in stage I-II NSCLC while morphologic tumour volume might be useful in cases with no lymph node involvement.
Key Points
•
Identifying variables that predict the prognosis of patients with NSCLC is important.
•
SUVmax in primary lung tumour is a useful independent prognostic variable
.
•
(CTvol) is an independent prognostic variable if no lymph nodes are involved
.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25929940</pmid><doi>10.1007/s00330-015-3754-8</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-8038-8161</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0938-7994 |
| ispartof | European radiology, 2015-11, Vol.25 (11), p.3361-3367 |
| issn | 0938-7994 1432-1084 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1720447464 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Carcinoma, Non-Small-Cell Lung - diagnostic imaging Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Chest Cone-Beam Computed Tomography Diagnostic Radiology Female Fluorodeoxyglucose F18 Humans Imaging Internal Medicine Interventional Radiology Lung cancer Lung Neoplasms - diagnostic imaging Lung Neoplasms - mortality Lung Neoplasms - pathology Lymphatic Metastasis - pathology Male Medicine Medicine & Public Health Multimodal Imaging Neoadjuvant Therapy Neoplasm Staging Neuroradiology Positron-Emission Tomography Prognosis Proportional Hazards Models Radiology Radiopharmaceuticals Retrospective Studies Tomography, X-Ray Computed Tumor Burden Ultrasound |
| title | Survival Prognostic Value of Morphological and Metabolic variables in Patients with Stage I and II Non-Small Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T03%3A30%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20Prognostic%20Value%20of%20Morphological%20and%20Metabolic%20variables%20in%20Patients%20with%20Stage%20I%20and%20II%20Non-Small%20Cell%20Lung%20Cancer&rft.jtitle=European%20radiology&rft.au=Domachevsky,%20L.&rft.date=2015-11-01&rft.volume=25&rft.issue=11&rft.spage=3361&rft.epage=3367&rft.pages=3361-3367&rft.issn=0938-7994&rft.eissn=1432-1084&rft_id=info:doi/10.1007/s00330-015-3754-8&rft_dat=%3Cproquest_cross%3E1720447464%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1719460006&rft_id=info:pmid/25929940&rfr_iscdi=true |